OMI - NYSE
Owens & Minor, Inc.
$2.68
+25%Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, which include supplier management, analytics, inventory management, and clinical supply management; and various programs to provide logistics and marketing solutions to its suppliers. The Global Products segment manufactures and sources medical surgical products for the prevention of healthcare-associated infections across the acute and alternate site channels. This segments products portfolio includes sterilization wraps, surgical drapes and gowns, facial protection products, protective apparel, medical exam gloves, custom and minor procedure kits, and other medical products. It provides its products and services to multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. The company was founded in 1882 and is headquartered in Richmond, Virginia.
At a Glance
Live SnapshotOwens & Minor, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Moderate margins typical of competitive industries. Monitor for pricing pressure or rising costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Owens & Minor, Inc. Income Statement
OMI • NYSE
| Owens & Minor, Inc. Income Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 | Dec 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
10.7B | 10.3B | 10B | 9.8B | 8.5B | 9.2B | 9.8B | 9.3B | 9.7B | 9.8B | 9.4B | 9.1B | 8.9B | 8.6B | 8.1B | 8B | 7.2B | 6.8B | 5.5B | 4.8B | |
GROSS PROFIT | ||||||||||||||||||||
(8.5B) | (8.2B) | (8.1B) | (8.3B) | (7.2B) | (8.1B) | (8.5B) | (8.1B) | (8.5B) | (8.6B) | (8.3B) | (8B) | (8B) | (7.8B) | (7.3B) | (7.3B) | (6.5B) | (6.1B) | (4.9B) | (4.3B) | |
2.2B | 2.1B | 1.8B | 1.5B | 1.3B | 1.1B | 1.4B | 1.2B | 1.2B | 1.2B | 1.2B | 1.1B | 924.7M | 857.5M | 807.7M | 786.9M | 717.3M | 715M | 596.8M | 516.1M | |
OPERATING INCOME | ||||||||||||||||||||
(2.4B) | (2B) | (1.7B) | (1.1B) | (1.1B) | (1B) | (1.3B) | (1B) | (963M) | (985.8M) | (967.6M) | (906.5M) | (717.7M) | (654M) | (611.8M) | (585.6M) | (536.5M) | (571.8M) | (494M) | (398.7M) | |
(1.9B) | (1.8B) | (1.6B) | (1.1B) | (1B) | (1B) | (1.3B) | (1B) | (970.4M) | (933.6M) | (927M) | (863.7M) | (682.6M) | (610.7M) | (585.5M) | (565.6M) | (521.4M) | (545.3M) | (468.8M) | (380.5M) | |
-207.8M | 104.5M | 142.9M | 368.5M | 204.1M | 99.4M | -392.2M | 89.3M | 199.6M | 200.4M | 159.5M | 198.1M | 196.8M | 203.5M | 195.9M | 201.3M | 180.7M | 143.2M | 102.8M | 117.4M | |
PRE-TAX INCOME | ||||||||||||||||||||
(143.8M) | (157.9M) | (128.9M) | (48.1M) | (83.4M) | (98.1M) | (71M) | (31.8M) | (27.1M) | (27.1M) | (18.2M) | (13.1M) | (13.4M) | (13.7M) | (14.3M) | (13M) | (16M) | (23M) | (13.3M) | (11.9M) | |
-143.8M | -157.9M | -128.9M | -48.1M | -83.4M | -98.1M | -71M | -31.8M | -27.1M | -27.1M | -18.2M | -13.1M | -13.4M | -13.7M | -14.3M | -13M | -16M | -23M | -13.3M | -11.9M | |
(517.1M) | (207.1M) | (128.6M) | (67.7M) | (34.1M) | (2.2M) | -4.4M | (4.9M) | -7.4M | (52.2M) | (40.7M) | (42.9M) | (35.1M) | (43.4M) | (26.3M) | (20M) | (15.1M) | (26.5M) | (25.2M) | (18.2M) | |
-149.6M | -159.2M | -132M | -91.7M | -94.2M | 0.0 | -74.7M | -31.8M | -27.1M | -27.1M | -33.1M | -13.1M | -19.1M | -13.7M | -14.3M | -13M | -16M | -23M | -24.7M | -11.9M | |
-357.4M | -54.7M | 10.9M | 276.8M | 109.9M | -28.7M | -469.2M | 57.5M | 172.5M | 173.2M | 126.5M | 185M | 183.4M | 189.8M | 181.6M | 188.2M | 164.7M | 120.2M | 78.1M | 105.6M | |
NET INCOME | ||||||||||||||||||||
(5.3M) | -13.4M | -11.5M | (55.2M) | (21.8M) | -6.1M | -32.2M | -15.3M | (63.8M) | (69.8M) | (60M) | (74.1M) | (74.4M) | (74.6M) | (71M) | (71.4M) | (63.5M) | (47.5M) | (29.3M) | (41.2M) | |
-362.7M | -41.3M | 22.4M | 221.6M | 29.9M | -62.4M | -437M | 72.8M | 108.8M | 103.4M | 66.5M | 110.9M | 109M | 115.2M | 110.6M | 104.7M | 93.3M | 72.7M | 48.8M | 64.4M |
SEC Filings
OMI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K/A 8-K/A 2025 (Amended) N/A | January 05, 2026 | December 24, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 31, 2025 | December 24, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 16, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 02, 2025 | December 02, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 31, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 07, 2025 | October 07, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 19, 2025 | September 15, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 11, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your OMI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.